HLA-A*03 as a predictor of response to Cancer Immunotherapy

Please contact Rachel.taylor@oncology.ox.ac.uk for the teams link to this talk

Vivek Naranbhai, MBChB, PhD, DPhil is a hematology-oncology fellow and immunogeneticist at Massachusetts General Hospital, the Dana-Farber Cancer Institute and Harvard Medical School. He is also a research associate and senior scientist at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) University of KwaZulu Natal. His work spans immunology, genetic epidemiology and bioinformatics in malignant and infectious diseases.

He obtained an MBChB (summa cum laude), Honours in Medical Microbiology (summa cum laude) and PhD (Immunology) concurrently at the Nelson R Mandela School of Medicine, South Africa working on Natural Killer cell responses in HIV. He then had an early leadership opportunity as the deputy-director of the Vaccine and Pathogenesis Programme at CAPRISA where he was involved in studies of Tenofovir gel for preventing HIV acquisition in women and demonstrated a link between systemic immune activation and HIV acquisition. As a Rhodes Scholar in Oxford, UK, he pursued a second PhD/DPhil in genetics of immune-mediated disease in the laboratory of Dr Adrian Hill. He was a postdoctoral scholar in the laboratory of Mary Carrington at the National Cancer Institute and completed internal medicine residency at Massachusetts General hospital, followed by fellowship in Hematology-Oncology at Massachusetts General Hospital. He is currently a postdoctoral fellow in the laboratory of John Iafrate where he works on immunology and genomics of cancer. His recent work involves elucidating features of antigen presentation that predict responses to immune-checkpoint blockade, and studying immune responses to COVID vaccination in patients with cancer. He co-leads the CANVAX study, a study of COVID vaccination in patients with cancer